Ars Pharmaceuticals Stock Performance
| SPRY Stock | 11.05 0.33 2.90% |
On a scale of 0 to 100, ARS Pharmaceuticals holds a performance score of 3. The firm shows a Beta (market volatility) of 3.31, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, ARS Pharmaceuticals will likely underperform. Please check ARS Pharmaceuticals' value at risk, kurtosis, period momentum indicator, as well as the relationship between the semi variance and day median price , to make a quick decision on whether ARS Pharmaceuticals' price patterns will revert.
Risk-Adjusted Performance
Soft
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in ARS Pharmaceuticals are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of fairly uncertain basic indicators, ARS Pharmaceuticals showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (12.86) | Five Day Return 2.06 | Year To Date Return (0.96) | Ten Year Return (54.48) | All Time Return (54.48) |
1 | Why ARS Pharmaceuticals Inc. stock could outperform in 2025 - July 2025 Sentiment Fast Moving Stock Watchlists - newser.com | 10/17/2025 |
2 | ARS Pharmaceuticals Inc Q3 2025 Earnings Report Preview What To Expect | 11/07/2025 |
3 | Disposition of 21828 shares by Dorsey Brian of ARS Pharmaceuticals, at 0.64 subject to Rule 16b-3 | 11/13/2025 |
4 | ARS Pharmaceuticals Inc. stock outlook for YEAR - Quarterly Growth Report High Accuracy Buy Signal Tips - newser.com | 11/19/2025 |
5 | 5,703 Shares in ARS Pharmaceuticals, Inc. SPRY Acquired by RiverPark Advisors LLC | 11/26/2025 |
6 | neffy Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions | 12/29/2025 |
7 | Acquisition by Lowenthal Richard E of 240000 shares of ARS Pharmaceuticals at 11.49 subject to Rule 16b-3 | 01/02/2026 |
8 | Assessing ARS Pharmaceuticals Valuation After China Approval Expands Neffy Allergy Market Reach | 01/08/2026 |
9 | ARS Pharma Gains China Approval for Neffy, Roth Reiterates Buy Rating | 01/09/2026 |
10 | ARS Pharmaceuticals Shares Down 12.3 percent Should You Sell | 01/12/2026 |
| Begin Period Cash Flow | 71 M | |
| Total Cashflows From Investing Activities | -106.1 M | |
| Free Cash Flow | 13 M |
ARS Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 1,097 in ARS Pharmaceuticals on October 15, 2025 and sell it today you would earn a total of 41.00 from holding ARS Pharmaceuticals or generate 3.74% return on investment over 90 days. ARS Pharmaceuticals is currently generating 0.2201% in daily expected returns and assumes 5.7685% risk (volatility on return distribution) over the 90 days horizon. In different words, 51% of stocks are less volatile than ARS, and 96% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
ARS Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for ARS Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as ARS Pharmaceuticals, and traders can use it to determine the average amount a ARS Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0382
| High Returns | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | SPRY | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average ARS Pharmaceuticals is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of ARS Pharmaceuticals by adding it to a well-diversified portfolio.
ARS Pharmaceuticals Fundamentals Growth
ARS Stock prices reflect investors' perceptions of the future prospects and financial health of ARS Pharmaceuticals, and ARS Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ARS Stock performance.
| Return On Equity | -0.46 | ||||
| Return On Asset | -0.19 | ||||
| Profit Margin | (0.56) % | ||||
| Operating Margin | (1.64) % | ||||
| Current Valuation | 1.1 B | ||||
| Shares Outstanding | 98.85 M | ||||
| Price To Book | 8.74 X | ||||
| Price To Sales | 9.04 X | ||||
| Revenue | 89.15 M | ||||
| Gross Profit | 114.87 M | ||||
| EBITDA | (3 M) | ||||
| Net Income | 8 M | ||||
| Total Debt | 42 K | ||||
| Book Value Per Share | 1.49 X | ||||
| Cash Flow From Operations | 13.55 M | ||||
| Earnings Per Share | (0.81) X | ||||
| Market Capitalization | 1.29 B | ||||
| Total Asset | 351.15 M | ||||
| Retained Earnings | (123.31 M) | ||||
| Working Capital | 310.86 M | ||||
About ARS Pharmaceuticals Performance
Evaluating ARS Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if ARS Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if ARS Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 1.8 K | 1.6 K | |
| Return On Tangible Assets | 0.02 | 0.02 | |
| Return On Capital Employed | (0.01) | (0.01) | |
| Return On Assets | 0.02 | 0.02 | |
| Return On Equity | 0.04 | 0.03 |
Things to note about ARS Pharmaceuticals performance evaluation
Checking the ongoing alerts about ARS Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for ARS Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| ARS Pharmaceuticals had very high historical volatility over the last 90 days | |
| ARS Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Over 87.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: ARS Pharmaceuticals Shares Down 12.3 percent Should You Sell |
- Analyzing ARS Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ARS Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining ARS Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ARS Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of ARS Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of ARS Pharmaceuticals' stock. These opinions can provide insight into ARS Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for ARS Stock Analysis
When running ARS Pharmaceuticals' price analysis, check to measure ARS Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ARS Pharmaceuticals is operating at the current time. Most of ARS Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ARS Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ARS Pharmaceuticals' price. Additionally, you may evaluate how the addition of ARS Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.